Overview

Selinexor, also referenced as KPT-330 and marketed as Sailidx in some regions, is a first-in-class oral inhibitor of the nuclear export protein XPO1 (also called CRM1). It belongs to the selective inhibitor of nuclear export (SINE) class. This article addresses the regulatory angle: how the drug reached the market, the post-marketing controls attached to it, and what compliance steps B2B buyers must verify.

Approval Pathway and Orphan Designation

Selinexor received its initial U.S. Food and Drug Administration approval in 2019 for a multiple myeloma indication, based on accelerated-review mechanisms available for serious conditions with unmet need. The molecule had previously been granted orphan-drug status for qualifying hematologic uses. These designations shape how the product is registered and supplied in different jurisdictions, since each market applies its own dossier and inspection requirements.

Risk Evaluation and Mitigation Strategy

Because selinexor carries notable hematologic and gastrointestinal toxicities, its U.S. distribution operates under a Risk Evaluation and Mitigation Strategy (REMS). The program imposes controls on prescribing, dispensing, and patient monitoring to manage known safety risks. Buyers and distributors handling the product must understand that REMS-linked medicines cannot move through ordinary wholesale channels without the required certified-prescriber and pharmacy participation.

Compliance Checklist for Procurement

For the 20mg*16 tablet presentation, sourcing teams should confirm valid manufacturing authorization, current Good Manufacturing Practice certificates, and lot-specific certificates of analysis. Importers should verify that the national marketing authorization matches the intended indication and that cold-chain or storage conditions stated by the manufacturer are met. Documenting the supply chain protects both the buyer and downstream clinical users.

Cross-Border Registration Considerations

Beyond the U.S. framework, each importing market maintains its own authorization and inspection regime, so a product cleared in one region cannot be assumed legal in another. Distributors must confirm that the specific Sailidx presentation matches the approved indication locally and that the manufacturer's certificates will satisfy customs and regulatory review. Variations in labeling language, shelf-life, and serialization requirements can block a shipment even when the active substance is identical. Building compliance verification into the sourcing workflow—rather than after a hold occurs—prevents costly delays for a medicine already subject to tight control.

FAQ

Q: What class of drug is selinexor?

A: It is a selective inhibitor of nuclear export (SINE) that blocks XPO1 (CRM1), a protein responsible for shuttling cargo out of the cell nucleus.

Q: Why does selinexor require a REMS program?

A: Regulators attached REMS to manage serious adverse effects through controlled prescribing, dispensing, and monitoring requirements.

Q: What documents should a buyer request before procurement?

A: Expect a valid marketing authorization, GMP certificate, and batch certificate of analysis, plus confirmation that import licensing matches the target market.